All In Biotech

Drug Trial Radar · NCT00721279

Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome

Sifrol Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary RLS

Last checked: Nov 19, 2026Latest source record: Jun 4, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

549

Actual

Start

Sep 2007

Primary completion

Oct 2008

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jul 24, 2008

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of the Post Market Surveillance (PMS) study are to evaluate the treatment effect of pramipexole on Restless Legs Syndrome (RLS) severity as measured by International Restless Legs Rating Scale and Global Clinical Impression - Improvement, to evaluate the time to reaching maintenance dose of pramipexole

Conditions

  • Restless Legs Syndrome

Interventions

  • Sifrol® (pramipexole dihydrochloride)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency Analysis for Baseline Pattern of RLS SymptomsTime frame: Baseline
  2. Change in Total Scores of IRLS (International Restless Legs Rating Scale)Time frame: Baseline and final visit (week12)
  3. Change in Global Clinical Impression - Improvement (CGI-I) ScaleTime frame: baseline and final visit (week 12)
  4. Frequency of Adverse EventsTime frame: Up to 16 weeks
  5. Correlation of the Change in IRLS at End of Titration and at Final VisitTime frame: Up to 12 weeks

Locations

127 sites in 1 country. Site status is shown where the registry gives one.

  • Boehringer Ingelheim Investigational Site

    Absam, Austria

  • Boehringer Ingelheim Investigational Site

    Absdorf, Austria

  • Boehringer Ingelheim Investigational Site

    Afritz, Austria

  • Boehringer Ingelheim Investigational Site

    Alkoven, Austria

  • Boehringer Ingelheim Investigational Site

    Altenmarkt/Zauchensee, Austria

  • Boehringer Ingelheim Investigational Site

    Anif, Austria

  • Boehringer Ingelheim Investigational Site

    Au, Austria

  • Boehringer Ingelheim Investigational Site

    Bad Goisern am Hallstättersee, Austria

  • Boehringer Ingelheim Investigational Site

    Bad Schallerbach, Austria

  • Boehringer Ingelheim Investigational Site

    Bad Vöslau, Austria

  • Boehringer Ingelheim Investigational Site

    Baden, Austria

  • Boehringer Ingelheim Investigational Site

    Bärnbach, Austria

  • Boehringer Ingelheim Investigational Site

    Bleiburg, Austria

  • Boehringer Ingelheim Investigational Site

    Bludenz, Austria

  • Boehringer Ingelheim Investigational Site

    Bregenz, Austria

  • Boehringer Ingelheim Investigational Site

    Bruck A.d. Mur, Austria

  • Boehringer Ingelheim Investigational Site

    Deutschkreutz, Austria

  • Boehringer Ingelheim Investigational Site

    Deutschlandsberg, Austria

  • Boehringer Ingelheim Investigational Site

    Dornbirn, Austria

  • Boehringer Ingelheim Investigational Site

    Ebensee, Austria

  • Boehringer Ingelheim Investigational Site

    Faak am See, Austria

  • Boehringer Ingelheim Investigational Site

    Ferlach, Austria

  • Boehringer Ingelheim Investigational Site

    Fieberbrunn, Austria

  • Boehringer Ingelheim Investigational Site

    Filzmoos, Austria

  • Boehringer Ingelheim Investigational Site

    Fischamend, Austria

  • Boehringer Ingelheim Investigational Site

    Fohnsdorf, Austria

  • Boehringer Ingelheim Investigational Site

    Fritzens, Austria

  • Boehringer Ingelheim Investigational Site

    Gallizien, Austria

  • Boehringer Ingelheim Investigational Site

    Gallspach, Austria

  • Boehringer Ingelheim Investigational Site

    Gaspoldshofen, Austria

  • Boehringer Ingelheim Investigational Site

    Gerasdorf bei Wien, Austria

  • Boehringer Ingelheim Investigational Site

    Gloggnitz, Austria

  • Boehringer Ingelheim Investigational Site

    Gmunden, Austria

  • Boehringer Ingelheim Investigational Site

    Grafenstein, Austria

  • Boehringer Ingelheim Investigational Site

    Graz, Austria

  • Boehringer Ingelheim Investigational Site

    Großklein, Austria

  • Boehringer Ingelheim Investigational Site

    Grünbach, Austria

  • Boehringer Ingelheim Investigational Site

    Haid, Austria

  • Boehringer Ingelheim Investigational Site

    Halbturn, Austria

  • Boehringer Ingelheim Investigational Site

    Hall in Tirol, Austria

Showing 40 of 127 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.